Comparative Pharmacology
Head-to-head clinical analysis: EXCEDRIN MIGRAINE RELIEF versus MIDOL LIQUID GELS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXCEDRIN MIGRAINE RELIEF versus MIDOL LIQUID GELS.
EXCEDRIN (MIGRAINE RELIEF) vs MIDOL LIQUID GELS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen: inhibits COX enzymes centrally, reducing prostaglandin synthesis; Aspirin: irreversibly acetylates COX-1 and COX-2, inhibiting prostaglandin synthesis and platelet aggregation; Caffeine: adenosine receptor antagonist, enhances analgesic effect by vasoconstriction and increased drug absorption.
Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis, and elevates pain threshold. Caffeine is a CNS stimulant and adenosine receptor antagonist that enhances analgesic effect. Pyrilamine maleate is an H1-antihistamine with sedative properties. The combination provides analgesic, antipyretic, and antihistaminic effects.
2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine) orally every 6 hours as needed, not to exceed 6 tablets in 24 hours.
2 capsules orally every 6 hours as needed. Maximum 8 capsules in 24 hours.
None Documented
None Documented
Acetaminophen: 2-3 hours (terminal); aspirin: 15-20 minutes (parent), salicylic acid: 2-3 hours (low dose), 15-30 hours (high dose); caffeine: 3-7 hours (adults). Clinical context: Half-lives prolonged in hepatic impairment, overdose, or renal failure.
Acetaminophen: 2-3 hours (therapeutic doses); prolonged in overdose (>12 hours) due to saturable metabolism. Caffeine: 3-5 hours (adults).
Renal excretion: acetaminophen ~3% unchanged, metabolites (glucuronide, sulfate, cysteine, mercapturate) ~85%; aspirin as salicylic acid ~10% unchanged, metabolites (salicyluric acid, glucuronides) ~75% renal; caffeine ~1-5% unchanged, metabolites (paraxanthine, theobromine, theophylline) ~70% renal. Biliary/fecal <5%.
Renal elimination: 85-90% as acetaminophen glucuronide and sulfate conjugates; 5-10% unchanged. Biliary/fecal: minimal (<5%).
Category C
Category C
Analgesic Combination
Analgesic Combination